New brain tumor drug tested in japanese children

NCT ID NCT07441707

Not yet recruiting Disease control Sponsor: Ipsen Source: ClinicalTrials.gov ↗

Summary

This early-stage study aims to check the safety and measure how the body processes the drug tovorafenib in Japanese children and young adults with recurrent low-grade brain tumors that have a specific genetic change (BRAF-altered). All participants will take the drug orally once a week for up to two years. The study will also see if the drug helps shrink the tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOW-GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.